PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (TRIAL IN PROGRESS)
W. Jurczak,
C. Dartigeas,
M. Coscia,
P. Ganly,
G. Al-Jazayrly,
C. Wang,
K. Bao,
C. C. Leow,
S. Shahda,
P. L. Zinzani
Affiliations
W. Jurczak
1 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
C. Dartigeas
2 Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Tours, France
M. Coscia
3 Molecular Biotechnology and Health Sciences, Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy
P. Ganly
4 Christchurch Hospital, Christchurch
G. Al-Jazayrly
5 Hollywood Presbyterian Medical Tower, Los Angeles
C. Wang
6 Elli Lily and Company, Indianapolis
K. Bao
7 Loxo Oncology at Lilly, Stamford, United States of America
C. C. Leow
7 Loxo Oncology at Lilly, Stamford, United States of America
S. Shahda
7 Loxo Oncology at Lilly, Stamford, United States of America
P. L. Zinzani
8 Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy
